Document:

EX-10.42

 Exhibit 10.42 

EMPLOYMENT AGREEMENT 

(Jeffrey Bloss) 

This Employment Agreement (this “Agreement’,) dated as of July 27, 2018 (the “Effective Date”), is
made by and between Tarveda Therapeutics, Inc., a Delaware corporation formerly named Blend Therapeutics, Inc., (the “Company” or “Tarveda”), and Jeffrey Bloss (“Executive”). 

WHEREAS, the Company wishes to employ Executive, and Executive wishes to be employed by the Company, upon the terms and
conditions set forth herein. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements
herein contained, the parties hereto agree as follows: 
 1.        Start Date. This
Agreement will be binding and in full force and effect as of the Effective Date. Executive’s first date of employment will be August 13, 2018 (the “Start Date”). 

2.        Title and Responsibilities. The Company hereby employs Executive to
perform those executive duties and services as the President and Chief Executive Officer of the Company (the “CEO”) shall assign to him from time to time, and Executive accepts employment with the Company, upon the terms and conditions
hereinafter set forth. Executive shall serve as the Chief Medical Officer of the Company and shall report to the CEO. The CEO shall have the right to review and change the responsibilities of Executive from time to time as he may deem necessary or
appropriate., subject to Executive’s right to terminate his employment for Good Reason (as defined in Section 12) Executive shall perform his duties under this Agreement principally out of the Company’s corporate headquarters
(currently Watertown, Massachusetts), or such other location as assigned. In addition, Executive shall make such business trips to such places as may be necessary or advisable for the efficient operations of the Company. 

3.        Dutv to Perform Services. Commencing on the Start Date, except as
provided below, Executive shall devote his full business time to rendering services to the Company hereunder, and shall exert all reasonable efforts in the rendering of such services. Nothing in this Agreement shall prohibit Executive from
(a) making and managing passive investments, or (b) participating in professional and charitable organizations in an unpaid capacity in a manner, and to an extent} that will not interfere with his duties to the Company and does not compete
with the activities of the Company. Executive agrees that in the rendering of all services to the Company and in all aspects of employment hereunder, he shall comply in all material respects with all directives, policies, standards and regulations
from time to time established by the Company, to the extent they are not in conflict with this Agreemep.t. The Company reserves the right to alter, supplement or rescind its employment procedures, benefits or policies at any time in its sole and
absolute discretion and without notice. 
 4.        Term of Agreement. The
term of this Agreement will commence on the Effective Date. There shall be no definite term of employment, and Executive shall be an employee at will. This Agreement will terminate upon the occurrence of a “Termination Event” subject to,
and in accordance with, Section 10, or earlier termination pursuant to Section 11. 

5.        Compensation. 

(a)        Base Salary. During the term of this Agreement, the Company shall pay
Executive a base salary, payable in equal installments in accordance with the Company’s standard schedule for salary payments to its employees, at an initial annual rate equal to $375,000. Executive’s base. salary shall be reviewed
annually by the Compensation Committee of the Board (the “Compensation Committee”), 

 
commencing in January 2019, and may be adjusted by the Company after each such review after discussions between the CEO and Executive, but shall not be decreased without the written consent of
Executive. 
 (b)         Annual Bonus. During the term of this
Agreement, beginning in calendar year 2018, Executive shall be eligible to receive an annual bonus (the “Annual Bonus”) in an amount up to 35% of Executive’s annual base salary (the “Maximum Amount”) contingent
upon satisfaction of performance goals, which shall be determined by the Compensation Committee at the beginning of each calendar year after consultation with the CEO. The Executive’s performance goals will be based upon the performance of the
Company and certain performance goals will be based more directly upon Executive’s performance. Following the close of the applicable calendar year, the Compensation Committee will determine in its sole discretion whether the Executive has
earned the Annual Bonus, and the amount of any Annual Bonus. Any Annual Bonus awarded shall be paid by no later than March 15 of the calendar year that begins immediately after the end of the calendar year to which the performance goals relate and
shall be subject to Executive serving as the Chief Medical Officer of the Company through the date that the Annual Bonus is paid. 

(c)         Stock Option. 

(i)         Stock Option. Subject to the approval by the Board, on the
Grant Date (as defined in Section 12), the Company shall grant to Executive an incentive stock option to the extent permissible (and otherwise a non-statutory stock option) (the “Stock
Option”) under the Company’s 2011 Stock Incentive Plan (the “Plan”) to purchase up to 1,158,815 shares of the Company’s common stock (“Common Stock”), at an exercise price that is no less than the
common stock’s fair market value on the Grant Date (as determined by the Board). 
 (ii)
        Vesting. 
 A.        The
Stock Option shall vest as to 25% of such shares on the first anniversary of the Start Date and the remainder shall vest in equal monthly portions over the following 36 months, for a total four-year vesting period. 

B.        With respect to the Stock Option, all vesting shall cease immediately upon
termination of Executive’s employment with the Company for any reason. 

C.        In the event that (i) there is a Change of Control and
(ii) Executive’s employment is terminated by the Company (including its successors) without Cause or by Executive for Good Reason (as defined in Section 12) on or within twelve (12) months after such Change of Control, and
provided that, if such termination occurs after a Change of Control, the Stock Option, and any additional equity grants of options or shares subject to vesting provisions, has been continued, assumed or substituted for by the Company, the buyer or
its affiliates or any surviving entity, then 100% of any then remaining unvested portion of the Stock Option, and any additional equity grants of options or shares subject to vesting provisions, (after giving effect to Section 5(d)(ii)(C))
shall become vested and exercisable in full immediately prior to Executive’s termination date. For clarity, if Executive transfers employment to the buyer or an affiliate of the buyer in connection with a Change of Control, this transfer will
not be considered a termination of employment for purposes of this Section 5(d)(ii). 

(iii)        Additional Equity. Executive may also be eligible to receive
additional grants of options or issuances of shares of the Company’s common stock, in amounts, if any, to be approved by the Company’s Board of Directors (the “Board”) in its discretion. 

 6.        Vacation; Holidays and
Sick Time: Benefits. 
 (a)        Vacation. Executive shall be eligible
for four weeks of paid vacation during each calendar year of this Agreement, pro-rated for any partial years. Vacation days accrued but not used by the end of any calendar year may be used in the subsequent
calendar year, provided that no more than five accrued vacation days may be carried over from one year to the next. 

(b)        Holidays and Sick Time. Executive shall be eligible for paid legal
and religious holidays and sick days in accordance with the Company’s normal policies in effect from time to time. 

(c)        Benefits. Subject to the satisfaction of any eligibility
requirements and any contribution therefor generally required of employees of the Company, commencing on the Start Date, Executive shall be eligible to participate in any and all employee benefit plans from time to time in effect for the full-time
employees of the Company generally (collectively, the “Benefit Plans”), but the Company shall not be required to establish any such program or plan. Such participation shall be subject to (i) the terms of the applicable plan
documents, and (ii) generally applicable Company policies. The Company may alter, modify, add to or delete its employee Benefit Plans at any time as it, in its sole discretion, determines to be appropriate. 

7.        Expenses. The Company shall pay or reimburse Executive for all
reasonable business expenses incurred or paid by Executive in connection with his employment by the Company in accordance with the Company’s policies in effect from time to time. 

8.        Nondisclosure, Noncompetition and Assignment of Intellectual Property
Agreement. The parties hereto have entered into a Nondisclosure, Noncompetition and Assignment of Intellectual Property Agreement (“Nondisclosure Agreement”), attached as Exhibit A, which may be amended by the parties from time
to time without regard to this Agreement. The Nondisclosure Agreement contains provisions that are intended by the parties to survive and do survive termination or expiration of this Agreement. 

9.        Other Obligations. 

(a)        Between Executive and Third Parties. Executive hereby represents,
warrants and agrees (i) that Executive has the full right to enter into this Agreement and perform the services required of him hereunder, without any restriction whatsoever; (ii) that in the course of performing services hereunder,
Executive will not violate the terms or conditions of any agreement between him and any third party, including former employers and clients, or infringe or wrongfully appropriate any patents, copyrights, trade secrets or other intellectual property
rights of any Person (as defined in Section 12) anywhere in the world; (iii} that Executive has not and will not disclose or use during his employment by the Company any confidential information that he acquired as a result of any previous
employment or consulting arrangement or under a previous obligation of confidentiality; and (iv) that Executive has disclosed to the Company in writing any and all continuing obligations to previous employers or others that require him not to
disclose any information to the Company. 
 (b)        Between the Company and
Third Parties. Executive acknowledges that the Company from time to time may have agreements with other Persons, including the government of the United States or other countries and agencies thereof, which impose obligations or restrictions on
the Company regarding inventions made during the course of work thereunder or regarding the confidential nature of such work. Executive agrees to be bound by all such obligations and restrictions and to take all action necessary to discharge the
obligations of the Company thereunder. 

  
 3 

 10.        Termination Without
Severance. 
 (a)        Termination Events. The following events shall each be
considered a “Termination Event” and, upon the occurrence of any of them, shall have the effect of immediately terminating the Company’s obligations under this Agreement, including its obligation to make any further payments
hereunder, but excluding the “Accrued Obligations” (as defined in Section 12): 

(i)        Executive’s death; 

(ii)        Executive’s Disability (as defined in Section 12); 

(iii)        The termination of Executive’s employment by the Company for Cause
(as defined in Section 12); or 
 (iv)        The termination of
Executive’s employment by Executive for any reason other than Good Reason (as defined in Section 12). 

(b)        Termination for Cause. To the extent practicable, any decision to
terminate Executive’s employment for Cause shall be made by the Board after Executive has received written notice from the Board including details of the grounds for termination for Cause, subject to any applicable cure provision in the
definition of “Cause” in Section 12, and has had a reasonable opportunity to be heard by the Board. Termination pursuant to Section 10(a)(iii) shall be without prejudice to any other right or remedy to which the Company may be
entitled, at law, in equity, under this Agreement or otherwise. 

(c)        Notice of Termination. Executive agrees to provide the Company with
a written notice of termination thirty (30) days prior to the effective date of a termination pursuant to Section 10(a)(iv). In such case at the Company’s option and sole discretion the Company may pay Executive his base salary for
thirty (30) days in lieu of this thirty (30) day notice period. 

(d)        Survival. Notwithstanding Executive’s termination of
employment pursuant to Section 10(a)(ii), 10(a)(iii) or 10(a)(iv), Executive’s covenants and obligations set forth in Sections 8, 10(d), 12 and 13 shall remain in effect and be fully enforceable in accordance with the provisions thereof.

 11.        Termination With Severance. 

(a)        Right to Terminate; Notice. In addition to the other termination
rights provided to the Company or Executive hereunder, the Company may terminate Executive’s employment without Cause and Executive may terminate Executive’s employment for Good Reason. 

(b)        Survival. In the event that Executive’s employment is
terminated by the Company without Cause, or by Executive for Good Reason, then Executive’s covenants and obligations set forth in Sections 8, 9, 11, 12, 13, 14(d), 16 and 17 shall remain in effect and be fully enforceable in accordance with the
provisions thereunder. 
 (c)        Severance. In the event that
Executive’s employment is terminated by the Company without Cause or by Executive for Good Reason, then Executive will receive the Accrued Obligations and, subject to Section l l(d), Executive shall be entitled to receive (i) the
installments of base salary set forth in Section S(a) not yet paid to Executive, payable when and as if Executive had continued to be employed by the Company until the six (6) month anniversary of the effective date of such termination (the
“Severance Period”), subject to standard payroll deductions and withholdings (the “Severance Payments’,) at the rate of Executive’s base salary in effect at the time of termination, without taking into

  
 4 

 
consideration any reduction in base salary that triggered a resignation for Good Reason, if applicable (ii) at the sole and final discretion of the Compensation Committee, a Pro Rata Bonus
(as defined in Section 12), which may be adjusted by the Compensation Committee in its sole discretion and which will be paid on the Company’s first regularly scheduled payroll date after the Release (as defined below) is effective,
subject to payroll deductions and withholdings; and (iii) provided that Executive timely elects and remains eligible for continued coverage under COBRA, then the Company shall pay the COBRA premiums necessary to continue Executive’s
medical insurance coverage in effect for Executive and Executive’s eligible dependents on the termination date for the Severance Period (provided that such COBRA reimbursement shall terminate on such earlier date as Executive is no longer
eligible for COBRA coverage). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that it cannot provide the foregoing benefit without potentially incurring financial costs or penalties under applicable law (including,
without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide Executive with a taxable monthly amount (which amount shall be based on the premium for the first month of COBRA coverage hereunder),
which payments shall be made regardless of whether Executive elects COBRA continuation coverage. If the Company elects to make such payments in lieu of paying such COBRA premiums, the payments will begin on the effective date of the Release and end
on the earlier of (A) the date on which Executive is no longer eligible for COBRA coverage and (B) the Severance Period. Nothing in this Section 11(c) shall be construed as imposing any obligation on the Company to maintain medical
insurance benefits of any nature at any time. 
 Severance Payments otherwise scheduled to be made under this Section 11(c)(i) prior
to the effective date of the release in Section 11(d) (namely, the date it can no longer be revoked) shall accrue and be paid on the first payroll date that follows such effective date of the release, with subsequent payments occurring on each
subsequent Company payroll date; provided, however, that if the period during which Executive may sign the release under Section 11(d) begins in one calendar year and ends in a second calendar year, then the payments provided in this
Section 11(c) shall not be paid or the first payment shall not occur until the first payroll date in the second calendar year. 

Notwithstanding the foregoing, if Executive’s employment is terminated without Cause or for Good Reason on or after a Change of Control,
then instead of the severance benefits described above, Executive will be eligible to receive the following enhanced severance benefits (the “CoC Severance Benefits”): the Severance Period for purposes of 11(c)(i), and the COBRA benefits
for purposes of 1l(c)(iii), both increase to twelve (12) months instead of six (6) months, and additionally, the Pro Rata Bonus described in 1l(c)(ii) will instead be in the total pro rata amount (calculated as described in the definition
of Pro Rata Bonus in Section 12) not subject to Compensation Committee discretion. The CoC Severance Benefits will be paid on the same schedules and upon the same terms and conditions described in the above paragraph in this Section 11(c).

 (d)        Release; Termination of Severance. Notwithstanding anything to
the contrary in Section 1 l(c), Executive shall not be entitled to receive any payments or benefits pursuant to Section 1l(c) (except for the Accrued Obligations) unless he first executes and delivers to the Company an effective general
release of claims against the Company and its affiliates in the form presented by the Company, which shall be substantially in the form attached hereto as Exhibit B· (the “Release”). The Release shall be provided to Executive within
fourteen (14) days of the effective date of termination. Executive must execute the Release within the consideration period specified therein, which shall in no event be more than 60 days. 

(e)        Termination of Severance. Without prejudice to any other right or
remedy to which the Company may be entitled, the Company may terminate its obligations under Section 11(c) if Executive breaches his obligations under Section 8 or any obligations under the Nondisclosure Agreement. 

  
 5 

 12.        Certain
Definitions. For purposes of this Agreement, the following terms shall have the meanings set forth below: 

“Accrued Obligations” means (1) the payment of base salary which is accrued at the date of
termination; (2) the dollar equivalent for Executive’s accrued and untaken vacation days as of the date of termination; (3) reimbursement for any unreimbursed expenses incurred through the date of termination, in accordance with
Company policy; (4) any unpaid bonus which has been awarded by the Compensation Committee and earned by Executive for any completed prior calendar year, payable when it otherwise would have been paid; and (5) benefits owed to Executive
under any qualified retirement plan or health and welfare benefit plan in which Executive was a participant in accordance with applicable law and the provisions of such plan. The Company will pay the Accrued Obligations to Executive, subject to
standard deductions and withholdings, on the next regular payroll date following the termination date, unless othe1wise required by applicable law. 

“Cause” means the occurrence of any of the following: (a) Executive’s material breach of this
Agreement or the Nondisclosure Agreement, which to the extent it is curable by the Executive, as determined by the Company in its sole discretion, is not cured within fifteen (15) days after written notice thereof is given to Executive by
Tarveda, (b) any act (other than resignation) or omission by the Executive which may have a material and adverse effect on Tarveda’s business or on Executive’s ability to perform services for Tarveda, including, without limitation,
the commission of any crime (other than minor traffic violations), or (c) Executive’s material misconduct or material neglect of his duties in connection with the business or affairs of Tarveda, which to the extent it is curable by the
Executive, as determined by the Company in its sole discretion, is not cured within fifteen (15) days after written notice thereof is given to you by Tarveda. 

“Change of Control” means “Change in Control” as defined in the Company’s 2011 Stock
Incentive Plan. 
 “Disability” means termination because Executive is unable due to a physical or mental
condition to perform the essential functions of Executive’s position with or without reasonable accommodation for 180 days in the aggregate during any twelve (12) month period or based on the written certification by two licensed
physicians of the likely continuation of such condition for such period. One of the physicians shall be chosen by the Company and the other shall be chosen by Executive, or by his or his representative. This definition shall be interpreted and
applied consistent with the Americans with Disabilities Act, the Family and Medical Leave Act, and other applicable law. 

“Good Reason” means Executive’s termination of his employment because of the occurrence of one of the
following, without his consent (i) the Company’s material breach of any one or more of the material provisions of this Agreement; (ii) a material reduction by the Company of Executive’s base salary of ten percent (10%) or more,
unless such reduction is made in connection with an across the board reduction in base salaries of all of the Company’s senior executives; (iii) the relocation of your p1incipal workplace more than fifty (50) miles from Watertown,
Massachusetts; (iv) a material diminution in Executive’s duties·, responsibilities or authority; or (v) a requirement that Executive report to a corporate officer or employee other than the CEO, unless such change follows a
Change of Control in which case Executive shall only have Good Reason to terminate his employment under this subsection (vi) if he is required to report to a corporate officer or employee instead of reporting directly to the highest ranking
medical officer of the surviving entity; provided, however, that, any such termination by Executive shall only be deemed for Good Reason pursuant to this definition if: (1) Executive gives the Company written notice of his intent to
terminate for Good Reason within thirty (30) days following the first occurrence of the condition(s) that he believes constitute(s) Good Reason, which notice shall describe such condition(s); (2) the Company fails to remedy such condition(s)
within thirty (30) days following receipt of the written 

  
 6 

 
notice (the “Cure Period”); and (3) Executive voluntarily terminates his employment within thirty (30) days following the end of the Cure Period. 

“Grant Date” means the date that the Board approves the award of the Stock Option, in which the Board
approves the number of shares of common stock subject to the Stock Option and its exercise price. 

“Person” means an individual, a corporation, an association, a partnership, real estate, a trust and any
other entity or organization. 
 “Pro Rata Bonus” means a pro rata bonus for the year of termination based
on the Maximum Amount for such calendar year and the relative number of days worked during such calendar year through the effective date of termination. 

13.        Miscellaneous. 

(a)        Entire Agreement: No Representations or Warranties. This Agreement
constitutes the entire agreement among the parties with respect to the subject matter hereof and supersedes the Prior Agreement, as amended, and all other prior agreements and understandings, both written and oral, between the parties with respect
to such subject matter. Executive acknowledges and agrees that, in accepting employment with the Company, he has not relied upon any agreements or representations not expressly set forth herein. The parties have entered into a separate Nondisclosure
Agreement and have or may enter into separate agreements related to equity. These separate agreements govern other aspects of the relationship between the parties, have or may have provisions that survive termination of Executive’s employment
under this Agreement, may be amended or superseded by the parties without regard to this Agreement and are enforceable according to their terms without regard to the enforcement provision of this Agreement. 

(b)        Assignability. This
Agret-111.ent shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. This Agreement is not intended to confer upon any Person other than the
parties hereto any rights or remedies hereunder. Except as expressly provided below, this Agreement shall not be assignable, in whole or in part, by either party without the prior written consent of the other party. Notwithstanding the foregoing,
the Company may assign its rights and obligations under this Agreement in whole or in part to any one or more subsidiaries, affiliates or successors. Any entity into which the Company is merged or with which the Company is consolidated or which
acquires the business of the Company or the business unit in which Executive is to be principally employed shall be deemed to be a successor of the Company for purposes hereof 

(c)        Amendments and Supplements. This Agreement may not be altered,
changed or amended, except by an instrument in writing signed by the parties hereto; provided, however, that no such alteration, change or amendment may be binding on the Company unless approved by the Board. 

(d)        No Waiver. The terms and conditions of this Agreement may be
waived only by a written instrument signed by the party waiving compliance. In the case of the Company, no waiver shall be effective unless approved by the Board. The failure of any party hereto to enforce at any time any of the provisions of this
Agreement shall in no way be construed to be a waiver of any such provision, nor in any way to affect the validity of this Agreement or any part hereof or the right of such party thereafter to enforce each and every such provision. No waiver of any
breach of or non-compliance with this Agreement shall be held to be a waiver of any other or subsequent breach or non-compliance. 

(e)        Construction of Agreement. A reference to a Section or Exhibit
shall mean a Section in or Exhibit to this Agreement unless otherwise expressly stated. The titles and headings herein are for reference purposes only and shall not in any manner limit the construction of this Agreement which

  
 7 

 
shall be considered as a whole. The words “include,” “includes” and “including” when used herein shall be deemed in each case to be followed by the words
“without limitation.” 
 (f)        Notice. Any notices required
hereunder to be in writing shall be deemed effectively given: (a)upon personal delivery to the party to be notified, (h) when sent by electronic mail or confirmed facsimile if sent during normal business hours of the recipient, and if not, then
on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next
day delivery, with written verification of receipt. All communications shall be sent to the Company at its primary office location and to Executive at Executive’s address as listed on the Company payroll or to Executive’s Company-issued
email address, or at such other address as the Company or Executive may designate by ten (10) days advance written notice to the other 

(g)        Governing Law; Forum Selection. This Agreement and the rights and
obligations of the parties hereto shall be governed by, and construed and enforced in accordance with, the substantive laws of the Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. Any action, suit or other legal
proceeding that is commenced to resolve any matter arising under or relating to any provision of this Agreement shall be commenced only in a state or federal court located in Massachusetts, and the Company and the Executive each consents to ,the
jurisdiction of such a court. 
 (h)        Remedies. Executive recognizes
that money damages alone may not adequately compensate the Company in the event of breach by Executive of this Agreement, and Executive therefore agrees that, in addition to all other remedies available to the Company at law, in equity or otherwise,
the Company may be entitled to injunctive relief for the enforcement hereof: All rights and remedies hereunder are cumulative and are in addition to and not exclusive of any other rights and remedies available at law, in equity, by agreement or
otherwise. 
 (i)        Validity. In the event that any provision of this
Agreement shall be determined to be unenforceable by reason of its extension for too great a period of time or over too large a geographic area or over too great a range of activities, it shall be interpreted to extend only over the maximum period
of time, geographic area or range of activities as to which it may be enforceable. If, after application of the preceding sentence, any provision of this Agreement shall be determined to be invalid, illegal or otherwise unenforceable by a court of
competent jurisdiction, the validity, legality and enforceability of the other provisions of this Agreement shall not be affected thereby. Except as otherwise provided in this Section 13, any invalid, illegal or unenforceable provision of this
Agreement shall be severable, and after any such severance all other provisions hereof shall remain .in full force and effect. 

G) Counterparts. This Agreement may be executed in one or more counterparts, all of which together shall constitute
one and the same Agreement. 
 (k) Application of Section 409A. Notwithstanding anything to the
contrary set forth herein, any payments and benefits provided under this Agreement that constitute “deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (“Code”)
and the regulations and other guidance thereunder and any state law of similar effect (collectively, “Section 409A”) shall not commence in connection with Executive’s termination of employment unless and until
Executive has also incurred a “separation from service” (as such term is defined in Treasury Regulation Section    l .409A-1(h) (“Separation From Service”),
unless the Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur the additional 20% tax under Section 409A. It is intended that each installment of severance pay provided for in
this Agreement is a separate “payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). For the avoidance of doubt, it is intended that severance payments set forth in this
Agreement satisfy, to the greatest extent possible, the 

  
 8 

 
exceptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A- 1(b)(4) and 1.409A-1(b)(9). If the Company (or, if
applicable, the successor entity thereto) determines that any payments or benefits constitute “deferred compensation” under Section 409A and Executive is, on the termination of service, a “specified employee” of the Company
or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code,, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the
payments and benefits shall be delayed until the earlier to occur of: (a) the date that is six months and one day after Executive’s Separation From Service, or (b) the date of Executive’s death (such applicable date, the
“Specified Employee Initial Payment Date”). On the Specified Employee Initial Payment Date, the Company (or the successor entity thereto, as applicable) shall (i) pay to Executive a lump sum amount equal to the sum of
the payments and benefits that Executive would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of such amounts had not been so delayed pursuant to this Section and (ii) commence
paying the balance of the payments and benefits in accordance with the applicable payment schedules set forth in this Agreement. All reimbursements provided under this Agreement shall be subject to the following requirements: (i) the amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement
in any other taxable year, (ii) all reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was
incurred, and (iii) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for any other benefit. It is intended that all payments and benefits under this Agreement shall
either comply with or be exempt from the requirements of Section 409A, and any ambiguity contained herein shall be interpreted in such manner so as to avoid adverse personal tax consequences under Section 409A. Notwithstanding the
foregoing, the Company shall in no event be obligated to indemnify Executive for any taxes or interest that may be assessed by the Internal Revenue Service pursuant to Section 409A of the Code to payments made pursuant to this Agreement. 

***** 
  

  
 9 

 IN WITNESS WHEREOF, the parties have caused this Employment Agreement to be
executed as an instrument under seal as of the date first written above. 
  

			
	TARVEDA THERAPEUTICS, INC.
		
	By:	 	 /s/Andrew Fromkin

	Name: Andrew Fromkin
	Title: CEO

  

	
	EXECUTIVE
	
	/s/Jeffrey Bloss
	Jeffrey Bloss

 Signature Page to Employment AgreementEX-10.43

 Exhibit 10.43 

TARVEDA THERAPEUTICS, INC. 

NONDISCLOSURE, NONCOMPETITION AND 

ASSIGNMENT OF INTELLECTUAL PROPERTY AGREEMENT 

In consideration and as a condition of my employment by Tarveda Therapeutics, Inc., a Delaware corporation (the “Company”),
and of the compensation to be paid to me, and in recognition of the fact that as an employee of the Company I will or may have access to confidential information, I agree with the Company as follows: 

1. Performance. I agree to perform my assigned duties diligently, conscientiously, and with reasonable skill, and shall comply with all
rules, procedures and standards promulgated from time to time by the Company with regard to my conduct and my access to and use of the Company’s property, equipment and facilities. Among such rules, procedures and standards are those governing
ethical and other professional standards for dealing with customers, government agencies, vendors, competitors, consultants, employees, and the public-at-large, rules
respecting attendance, punctuality, and hours of work, security provisions designed to protect Company property and the personal security of Company employees, and rules and procedures designed to protect the confidentiality of proprietary
information. The Company agrees to make reasonable efforts to inform me of such rules, standards and procedures as are in effect from time to time. 

2. No Conflicts. I hereby represent, warrant and agree (i) that I have the full right to enter into this Agreement and perform the
services required of me hereunder, without any restriction whatsoever; (ii) that in the course of performing services hereunder, I will not violate the terms or conditions of any agreement between me and any third party or infringe or
wrongfully appropriate any patents, copyrights, trade secrets or other intellectual property rights of any person or entity anywhere in the world; (iii) that I have not and will not disclose or use during my employment by the Company any
confidential information that I acquired as a result of any previous employment or consulting arrangement or under a previous obligation of confidentiality; and (iv) that I have disclosed to the Company in writing any and all continuing
obligations to previous employers or others that require me not to disclose any information to the Company. 
 3. “Field of
Interest” shall mean the field of oncology or other disease areas where the Company is actively discovering, developing, or commercializing: (i) therapeutic or diagnostic products that feature an active pharmaceutical ingredient
(“API”) or diagnostic agent conjugated to a targeting ligand that may comprise a natural peptide, engineered or modified peptide, small molecule, or other targeting moiety; or (ii) approaches for modifying the pharmacokinetics and/or
modifying the target tissue or normal tissue delivery of those therapeutics and/or diagnostics either defined in (i) or otherwise being developed by the Company, including but not limited to: (x) incorporation into particles (including
nanoparticles, liposomes, exosomes or other particle constructs), (y) attachment or association with other chemistries, such as attachment to albumin or PEG, and (z) modifying the pharmacokinetics and/or the target tissue or normal tissue
distribution. 

 4. Confidential Information. I understand that the Company continually obtains and
develops valuable proprietary and confidential information concerning its scientific or business affairs (the “Confidential Information” (as defined below)) which may become known to me in connection with my employment by the Company. I
acknowledge that all Confidential Information (as defined below), whether or not in writing and whether or not labeled or identified as confidential or proprietary, is and shall remain the exclusive property of the Company or the third party
providing such information to me or the Company. While engaged by the Company and thereafter, I shall not, directly or indirectly, use any Confidential Information (as defined below) other than pursuant to my employment by and for the benefit of the
Company, or disclose or otherwise make available any Confidential Information to anyone outside of the Company, whether by private communication, public address, publication or otherwise, or disclose or otherwise make available any Confidential
Information to anyone within the Company who has not been authorized to receive such information, except as directed in writing by an authorized representative of the Company. The term “Confidential Information” as used throughout
this Agreement shall mean all trade secrets, proprietary information, know- how, data, designs, specifications, processes, customer lists and other technical or business information (and any tangible evidence, record or representation thereof),
disclosed to me at any time, whether before or after execution of this Agreement, whether prepared, conceived or developed by a consultant or an employee of the Company (including myself) or received by the Company from an outside source, which is
in the possession of the Company (whether or not the property of the Company), which in any way relates to the present or future business of the Company, which is maintained in confidence by the Company, or which might permit the Company or its
customers to obtain a competitive advantage over competitors who do not have access to such trade secrets, proprietary information, or other data or information. Without limiting the generality of the foregoing, Confidential Information shall
include without limitation: 
 (a) any idea, improvement, invention, innovation, development, concept, technical or clinical data, design,
formula, device, pattern, sequence, method, process, machine, manufacturing method, composition of matter, computer program, or software, source code, object code, algorithm, model, diagram, flow chart, chip masking specification, user manual,
training or service manual, product specification, plan for a new or revised product, sample, compilation of information, or work in process, or parts thereof, and any and all revisions and improvements relating to any of the foregoing (in each case
whether or not reduced to tangible form); and 
 (b) the name of any employee, consultant, supplier, customer or prospective customer, or any
other customer or prospective customer information, any sales plan, marketing material, plan or survey, business plan or opportunity, product or development plan or specification, business proposal, financial record, or business record or other
record or information relating to the present or proposed business of the Company or any customer. 
 Confidential Information is contained
in various media, including without limitation, patent applications, research data and observations, records of clinical trials, computer programs in object and/or source code, technical specifications, laboratory notebooks, supplier and customer
lists, internal financial data and other documents and records of the Company. 
 I may disclose Confidential Information to
(i) directors, employees, consultants and representatives of the Company, to (ii) my accountants, financial advisors and counsel, who have a bona fide need to know such information and who are bound by an obligation not to use or disclose
such information without authorization from the Company and to (iii) other parties that enter into confidentiality or non-disclosure agreements with the Company and to whom such

  
 2 

 
Confidential Information will be disclosed for legitimate business purposes of the Company. I agree that I shall use such Confidential Information only in the performance of my duties for the
Company and in accordance with any Company policies with respect to the protection of Confidential Information. I agree not to use such Confidential Information for my own benefit or for the benefit of any other person or business entity. 

I agree to exercise all reasonable precautions to protect the integrity and confidentiality of Confidential Information in my possession and
not to remove any materials containing Confidential Information from the Company’s premises except to the extent necessary to my employment for the benefit of the Company. Upon the termination of my employment by the Company, or at any time
upon the Company’s request, I shall return immediately to the Company any and all tangible materials containing any Confidential Information then in my possession or under my control and destroy any intangible copies of such Confidential
Information. 
 Notwithstanding the foregoing, the term Confidential Information shall not apply to information which the Company has
voluntarily disclosed to the public without restriction, or which has otherwise lawfully entered the public domain. 
 I understand that the
Company from time to time has in its possession information which is claimed by customers and others to be proprietary and which the Company has agreed to keep confidential. I agree that all such information shall be Confidential Information for
purposes of this Agreement. 
 5. Ownership and Assignment of Intellectual Property. I agree that all originals and all copies of all
manuscripts, drawings, prints, manuals, diagrams, letters, notes, notebooks, reports, models, records, files, memoranda, plans, sketches and all other documents and materials containing, representing, evidencing, recording, or constituting any
Confidential Information (as defined in Section 4 above), however and whenever produced (whether by myself or others) during the course of my employment with the Company, shall be the sole property of the Company. 

I agree that all Confidential Information and all other discoveries, inventions, ideas, concepts, trademarks, service marks, logos, processes,
products, formulas, computer programs or software, source codes, object codes, algorithms, machines, apparatuses, chemical or biological materials, items of manufacture or composition of matter, or any new uses therefor or improvements thereon, or
any new designs or modifications or configurations of any kind, or works of authorship of any kind, including, without limitation, compilations and derivative works, whether or not patentable or copyrightable, conceived, developed, reduced to
practice or tangible medium or otherwise made by me, either alone or with others, and in any way related to the Field of Interest or to tasks assigned to me during the course of my employment by the Company, whether before or after execution of this
Agreement, whether or not made during my regular working hours, whether or not conceived, developed, reduced to practice or made on the Company’s premises and whether or not disclosed by me to the Company (collectively “Company
Inventions” and each individually an “Invention”), and any and all services and products which embody, emulate or employ any such Invention or Confidential Information shall be the sole property of the Company and all
copyrights, patents, patent rights, trademarks and reproduction rights to, and other proprietary rights in, each such Invention or Confidential Information, whether or not patentable or copyrightable, shall belong exclusively to the Company. 

  
 3 

 I agree to, and hereby do, assign to the Company all my right, title and interest throughout
the world in and to all Company Inventions and to anything tangible which evidences, incorporates, constitutes, represents or records any Invention. I agree that all Company Inventions shall constitute works made for hire under the copyright laws of
the United States and hereby assign and, to the extent any such assignment cannot be made at present, I hereby agree to assign to the Company all copyrights, patents and other proprietary rights I may have in any Company Inventions, together with
the right to file for and/or own wholly without restriction United States and foreign patents, trademarks, and copyrights. I agree to waive, and hereby waive, all moral rights or proprietary rights in or to any Company Inventions and, to the extent
that such rights may not be waived, agree not to assert such rights against the Company or its licensees, successors or assigns. 
 During
and after my employment by the Company, I shall cooperate with the Company, at the Company’s expense, in obtaining proprietary protection for the Company Inventions and I shall execute all documents which the Company shall reasonably request in
order to perfect the Company’s rights in the Company Inventions. I hereby appoint the Company my attorney-in-fact to execute and deliver any such documents on my
behalf in the event I should fail or refuse to do so within a reasonable period following the Company’s request. It is understood that my reasonable out-of-pocket
expenses incurred at the request of the Company under this Section will be reimbursed by the Company. 
 I hereby certify Exhibit A
contains a complete list of all inventions related to the business or proposed business of the Company, made, conceived or first reduced to practice by me, under my direction or jointly with others prior to my employment with the Company (the
“Prior Inventions”) and which are not assigned to the Company hereunder. If no such list is attached, I represent that there are no such Prior Inventions. 

6. Obligation to Keep Records. I shall make and maintain adequate and current written records of all Company Inventions, including
notebooks and invention disclosures, which records shall be available to and remain the property of the Company at all times. I shall disclose all Company Inventions promptly, fully and in writing to the Company immediately upon production or
development of the same and at any time upon request. 
 7. Obligation to Cooperate. I will, at any time during my engagement, or
after it terminates, upon request of the Company, execute all documents and perform all lawful acts which the Company considers necessary or advisable to secure its rights hereunder and to carry out the intent of this Agreement without further
compensation of any kind. Without limiting the generality of the foregoing, I will assist the Company in any reasonable manner to obtain for its own benefit patents or copyrights in any and all countrie s with respect to all Company Inventions
assigned pursuant to Section 5, and I will execute, when requested, patent and other applications and assignments thereof to the Company, or persons designated by it, and any other lawful documents deemed necessary by the Company to can-y out the purposes of this Agreement, and I will further assist the Company in every way to enforce 

  
 4 

 
any patents and copyrights obtained, including, without limitation, testifying in any suit or proceeding involving any of said patents or copyrights or executing any documents deemed necessary by
the Company, all without further consideration than provided for herein. It is understood that reasonable out-of-pocket expenses of my assistance incurred at the request
of the Company under this Section will be reimbursed by the Company. 
 8. Noncompetition. During my engagement with the Company and
for a period of 12 months after the termination of my engagement with the Company for any reason (the “Restricted Period”), I shall not, on my own behalf, or as owner, manager, stockholder, consultant, director, officer, or employee
of any business entity (except as a holder of not more than one (1%) percent of the stock of a publicly held company) participate, directly or indirectly, in any capacity, in any business activity that is related to the Field of Interest without
prior written consent from the Company, which shall not be unreasonably withheld. 
 9. Nonsolicitation of Personnel. During the
Restricted Period, I shall not solicit, induce, attempt to hire, or hire any employee of, or consultant to, the Company (or any person who may have been employed or engaged by the Company during the term of my engagement with the Company), or assist
in such hiring by any other person or business entity or encourage any such employee or consultant to terminate his or her employment or engagement with the Company. 

10. Nonsolicitation of Customers. During the Restricted Period, and except to the extent required in order to perform my duties under an
employment or consulting agreement with the Company, I shall not solicit, divert or take away, or attempt to divert or take away, the business or patronage of any of the clients, customers or accounts, or prospective clients, customers or accounts,
of the Company which were contacted, solicited or served by me in connection with my engagement by the Company; provided, however, that I may solicit business from such customers and prospective customers if it is not related to the Field of
Interest. 
 11. Return of Property. Upon termination of my engagement with the Company, or at any other time upon request of the
Company, I shall return promptly any and all customer or prospective customer lists , other customer or prospective customer information or related materials, computer programs, software, electronic data, specifications, drawings, blueprints, data
storage devices, reproductions, sketches, notes, notebooks, memoranda, reports, records, proposals, business plans, or copies of them, other documents or materials, tools, equipment, or other property belonging to the Company or its customers which
I may then possess or have under my control. I further agree that upon termination of engagement I shall not take with me any documents or data in any form or of any description containing or pertaining to Confidential Information or Company
Inventions. 
 12. Other Obligations. I acknowledge that the Company from time to time may have agreements with other persons,
including the government of the United States or other countries and agencies thereof, which impose obligations or restrictions on the Company regarding inventions made during the course of work thereunder or regarding the confidential nature of
such work. I agree to be bound by all such obligations and restrictions and to take all action necessary to discharge the obligations of the Company thereunder. 

  
 5 

 13. Miscellaneous 

(a) This Agreement contains the entire and only agreement between me and the Company with respect to the subject matter hereof, superseding any
previous oral or written communications , representations, understandings, or agreements with the Company or any officer or representative hereof. In the event of any inconsistency between this Agreement and any other contract between me and the
Company, the provisions of this Agreement shall prevail. 
 (b) My obligations under this Agreement shall survive the termination of my
engagement with the Company regardless of the manner of or reasons for such termination, and regardless of whether such termination constitutes a breach of any other agreement I may have with the Company. My obligations under this Agreement shall be
binding upon my heirs, assigns, executors, administrators and representatives, and the provisions of this Agreement shall inure to the benefit of and be binding on the successors and assigns of the Company. 

(c) If any provision of this Agreement shall be determined to be unenforceable by any court of competent jurisdiction by reason of its
extending for too great a period of time or over too large a geographic area or over too great a range of activities, it shall be interpreted to extend only over the maximum period of time, geographic area or range of activities as to which it may
be enforceable. If, after application of the immediately preceding sentence, any provision of this Agreement shall be determined to be invalid, illegal or otherwise unenforceable by any court of competent jurisdiction, the validity, legality and
enforceability of the other provisions of this Agreement shall not be affected thereby. Except as otherwise provided in this paragraph, any invalid, illegal or unenforceable provision of this Agreement shall be severable, and after any such
severance, all other provisions hereof shall remain in full force and effect. 
 (d) I acknowledge and agree that violation of this Agreement
by me would cause irreparable harm to the Company not adequately compensable by money damages alone, and I therefore agree that, in addition to all other remedies available to the Company at law, in equity or otherwise, the Company shall be entitled
to injunctive relief to prevent an actual or threatened violation of this Agreement and to enforce the provisions hereof, without showing or proving any actual damage to the Company or posting any bond in connection therewith. 

(e) No failure by the Company to insist upon strict compliance with any of the terms, covenants, or conditions hereof, and no delay or omission
by the Company in exercising any right under this Agreement, will operate as a waiver of such terms, covenants, conditions or rights. A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be
construed as a bar to or waiver of any right on any other occasion. 
 (f) This Agreement may not be changed, modified, released, discharged,
abandoned, or otherwise amended, in whole or in part, except by an instrument in writing signed by me and the Company. 
 (g) This Agreement
shall be governed by, and construed and enforced in accordance with, the laws of The Commonwealth of Massachusetts, without regard to its principles of conflicts of laws. This Agreement is executed under seal. 

* * * 

  
 6 

 BY PLACING MY SIGNATURE HEREUNDER, I ACKNOWLEDGE THAT I HAVE READ ALL THE PROVISIONS OF THIS
NONDISCLOSURE, NONCOMPETITION AND ASSIGNMENT OF INTELLECTUAL PROPERTY AGREEMENT AND THAT I AGREE TO ALL OF ITS TERMS. 
  

							
	Date: ______________________	 		 	  

		 		 	[Executive]
		 		 	Address:
			
		 		 	Accepted and Agreed:
			
		 		 	TARVEDA THERAPEUTICS, INC.
			
	Date: ______________________	 		 	By:
                                         
                                       
		 		 	Name:	 	
		 		 	Title:	 	

  
 7 

 EXHIBIT A 

Prior Inventions 
 The following is a
complete list of all Prior Inventions 
 ______     No Prior Inventions 

______     See below for description of Prior Inventions 
  

			
	PAT. NO.	  	Title

  
 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]